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ModelingIron is an essential nutrient which must be provided in sufﬁcient amounts to support growth of eukaryotic cells.
All organisms devote specialized pathways to ensure proper delivery. Yet, a quantitative assessment of the
intra-cellular iron concentration needed to allow the cell cycle to proceed inmammalian cells ismissing. Starting
from iron-depleted cell lines or primary hematopoietic progenitors prepared with clinically implemented iron
chelators, replenishment via transferrin and other iron sources has been quantitatively monitored through the
main endogenous markers of the cellular iron status, namely proteins involved in the uptake (transferrin
receptor), the storage (ferritin), and the sensing (Iron Regulatory Proteins) of iron. When correlated with
measurements of iron concentrations and indicators of growth, this minimally intrusive approach provided an
unprecedented estimate of the intracellular iron concentration acting upon iron-centered regulatory pathways.
The data were analyzed with the help of a previously developed theoretical treatment of cellular iron regulation.
Theminimal cellular iron concentration required for cell divisionwas named functional iron concentration (FIC) to
distinguish it from previous estimates of the cellular labile iron. The FIC falls in the low nanomolar range for all
studied cells, including hematopoietic progenitors. These data shed new light on basic aspects of cellular iron
homeostasis by demonstrating that sensing and regulation of iron occur well below the concentrations requiring
storage or becoming noxious in pathological conditions. The quantitative assessment provided here is relevant
for monitoring treatments of conditions in which iron provision must be controlled to avoid unwanted cellular
proliferation.
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Iron is required to maintain viability and to support growth of
almost all kinds of cells. In eukaryotes, it is abundantly present in the
electron-transfer centers of the mitochondrial respiratory chain, for in-
stance, and, more generally, it participates at the active sites of a myriad
of proteins and enzymes. Consequently, iron is mandatory for cellular
proliferation [1], and iron removal from the growth medium generally
stops the cell cycle at the G1/S transition. One contributing factor to
this blockade is the iron-dependent enzyme ribonucleotide reductase,
which relies on a subunit containing a tyrosyl-di-iron cofactor [2]. The
arrest of the cell cycle induced by iron chelators justiﬁes considering
these compounds as anti-neoplastic agents [3].
In metazoans, the most iron demanding pathway is erythropoiesis
since iron is the anchoring site of oxygen in hemoglobin, a protein sup-
plying oxygen to tissues. Iron-deﬁcient individuals suffer from anemia,
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andwhich is themostwidespread single nutrient deﬁciencyworldwide
[4,5]. Iron provision for hematopoiesis is delivered by transferrin (Tf), a
circulating glycoprotein which can be easily measured together with its
iron load to gauge the iron status. Although the critical levels of this use-
ful biomarker have been set a long time ago, it remains unclear how
much Tf-delivered iron is needed to support proliferation of cells that
must divide to maintain homeostasis or to fulﬁll speciﬁc functions.
Throughout hematopoiesis, cells must properly handle iron according
to the speciﬁc requirements of the different stages, from renewal of
stem cells to full differentiation of specialized blood components [6].
Cells need to maintain the proper level of iron availability, and this
requirement is challenged in transfusion-induced iron overload or,
conversely, by neoplasm-triggered large iron consumption. The former
situation occurs in cases of thalassemia [7] and myelodysplastic
syndromes [8], for instance. The latter applies to cancer cells in general,
acute myeloid leukemia clones in particular, for which ample iron
provision is needed to support growth, particularly in the blast crisis.
The pivotal role of iron in such circumstances has recently been clearly
evidenced by the redirection of proliferating blasts into the monocyte
lineage with a treatment including iron chelation [9–11].
To clarify conditions underwhich cell proliferation occurs, the quan-
titative iron needs of model cell lines and of hematological progenitors
for ampliﬁcation have been evaluatedherein. The implemented integra-
tive approachminimally perturbed cells, and it allowed us to show that
proliferation is supported by smaller amounts of iron than assumed
before.With the help of a recently developed theoretical model of cellu-
lar iron homeostasis, these data should help understand the role of iron
deregulation in a wealth of pathological conditions, and they will have
to be considered for a better implementation of the therapeutic
strategies targeting iron-dependent pathways.
2. Materials and methods
2.1. Reagents
All reagents were obtained from Sigma-Aldrich unless stated other-
wise. Human holo-transferrin (i.e. iron-loaded transferrin, Sigma
T4132) was iron saturated with 2 Fe atoms/molecule. The iron content
of human apo-transferrin (apo-Tf), i.e. the protein devoid of iron, was
measured by inductively coupled plasma-mass spectrometry at less
than 0.025 iron atom/transferrin molecule. Recombinant human Iron
Regulatory Proteins (IRP) 1 and 2 were obtained as previously detailed
[12,13].
2.2. Cell lines
The cell lines used in the present study originated from the ATCC
biological resource. The human myeloid leukemia KG1 and K562 cells
were grown in RPMI-1640 medium, supplemented with 10% fetal
bovine serum (Biowest, origin: South America, batch containing
1.7 mg of iron/l), 1% L-glutamine, 100 U of penicillin/ml and 0.1 mg
steptomycin/ml at 37 °C with 5% CO2. As a rapidly growing cell model
signiﬁcantly different from the above cell lines, HeLa cells were routine-
ly maintained in Dulbecco's modiﬁed Eagle medium (DMEM) supple-
mented as above for leukemic cell lines. The iron-containing DMEM
was replaced by RPMI after iron depletion for direct comparison of the
iron-requirements of the HeLa cells as compared to the other cells
used in this work.
2.3. Puriﬁcation of CD34+ progenitors
CD34+ cells were obtained from cord blood after Ficoll-Hypaque
(Abcys - Eurobio) density gradient separation and they were isolated
by two steps of immunomagnetic separation (Miltenyi Biotec), on
large then medium size columns, successively. Cord blood procedureswere approved by the French Blood Service's Institutional Review
Board, and samples were obtained from healthy donors who gave
informed consent.
2.4. Iron depletion and proliferation assay for cell lines
After routinemaintenance in richmedia, cell lines were handled in a
minimal medium composed of RPMI-1640, 1% treated (see below) bo-
vine serum albumin (BSA), 30 nM sodium selenite, 1% L-glutamine,
100 U of penicillin/ml and 0.1 mg steptomycin/ml at 37 °C in 5% CO2.
In the case of HeLa cells, the minimal medium was used after adhesion
in the conventional rich medium. To remove as much iron as possible,
theBSApowderwasdissolved in 10mMHEPES buffer pH7.3 containing
5mM EDTA before dialysis with successive baths of distilledwater until
reaching an EDTA concentration below 1 nM. Beforehand, distilled
water was ﬁltered through Chelex cation exchange resin (BioRad). The
BSA concentration was estimated by spectrophotometry at 280 nm
(ε= 39,600 M−1 cm−1).
Cells were seeded at 5 × 105 cell/ml in minimal medium without
added iron or Tf, and the chelating agent was added for 24 h. Deferox-
amine mesylate salt was used at 200 μM and deferiprone at 500 μM.
The depletion medium was replaced by the minimal medium supple-
mented with the wanted source of iron. Cells were further kept for
24 h, which is the optimum duration to measure growth at low iron
concentrations before cell death, and the cells were then processed.
Viable cells were determined by Trypan blue staining and quantiﬁed
with a Luna™ counter (Logos).
2.5. Ampliﬁcation, iron depletion, and proliferation assay for CD34 cells
A synthetic minimal mediumwas used to control iron supply. It was
composed of Iscove's Modiﬁed Dulbecco's Medium (IMDM, Life Tech-
nologies), 1% iron-depleted albumin (as described above), 200 μg/ml
insulin, 0.1 mM β-mercaptoethanol and the StemMACS HSC expansion
cocktail (TPO/FLT3/SCF -Miltenyi Biotec) at 37 °C in 5% CO2. Freshly iso-
lated CD34+ cells were seeded at 1 × 105 cells/ml and ampliﬁed for
three days in the above minimal medium supplemented with 1.25 μM
holo-Tf. Iron depletion and further experiments were carried out in
the samemedium inwhich the iron sourcewas preciselymonitored. Vi-
able cells were determined by Trypan blue staining in Neubauer slides.
2.6. Cell cycle assays
Cells were rinsed and suspended at 3 × 106 cells/ml in Phosphate
Buffered Saline (PBS) solution. They were ﬁxed by slowly adding cold
ethanol up to 50% (v:v) with thorough mixing. The suspension was
left at 4 °C for one hour, the cells were centrifuged, washed with cold
PBS, and suspended in PBS (4 × 106 cells/ml). RNA were degraded by
0.5mg/ml RNAse A (Thermo Scientiﬁc) at 37 °C for 1 h, and cells were la-
beled by 10 μg/ml propidium iodide. The ﬂuorescence was measured by
ﬂow cytometry with the LSR Fortessa™ cell analyzer (Becton Dickinson)
using the 488 nm sapphire laser. The data were analyzedwith theModﬁt
LT v3.2 software (Verity Software House).
2.7. Iron measurements
Iron concentrations were determined by Inductively Coupled
Plasma-Mass Spectrometry (ICP-MS) using a XSERIES 2 analyzer
(Thermo Scientiﬁc). Cellular pellets were suspended at 4000–
8000 cells/μl of water. The volume corresponding to 8 × 105 cells
was diluted (1:25) and mixed (1:1 v/v) with 1% nitric acid before
analysis. Raw results were converted to cell associated concentra-
tions by considering the estimated volumes of KG1 and K562 cells,
0.8 and 2.5 pL, respectively, in agreement with previously
published values for the latter [14]. Gallium was used as internal
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directly treated with acid before analysis.2.8. IRP activity measurement
IRP1 and IRP2 RNA-binding activities were measured by electropho-
retic mobility shift assays with 3 μg of total protein extracts. The minimal
sequence of human ferritin H-chain Iron Responsive Element (IRE) [12]
was biotin-labeled with biotinylated cytidine (bis)phosphate using T4
RNA ligase (Thermo Scientiﬁc). The IRE-IRP reaction was carried out as
previously described [12] and the complexes were separated on non-
denaturing 4% PAGE in 0.5X TBE, transferred onto Hybond™ N+ mem-
brane (GE Healthcare) and the biotinylated bandswere detected after in-
teraction with the streptavidin-horseradish peroxidase conjugate by the
chemiluminescent luminol product. Quantitation of the signals was
donewith the Image J software (v1.47,WayneRasband, ResearchServices
Branch, National Institute of Mental Health, Bethesda, Maryland, USA).2.9. Western blotting
Twenty to forty μg of total proteinswere resolved by sodiumdodecyl
sulfate-polyacrylamide gel electrophoresis on 8% or 15% gels, and pro-
teins were transferred to polyvinylidene diﬂuoride membranes. For
CD34+ protein extracts, 8–16% gradient gels (Gene Bio-Application
Ltd) were used. The blots were saturated with 10% non-fat milk in
PBS-Tween 0.2% and probed overnight at 4 °C with antibodies (all
produced in rabbit) against IRP1 (1:500) [15], ferritin (1:1000, Cell
Signaling), heme oxygenase-1 (1:1000, Assay Designs), transferrin
receptor 1 (1:1000, Abcam), and actin (1:250, SigmaAldrich). Following
three washes with PBS-Tween 0.2%, the blots were incubated with
peroxidase-coupled goat anti-rabbit IgG (Bethyl) at a dilution of
1:5000 for 1 h at room temperature, followed by detection with the
Pierce ECL western blotting substrate (Thermo Scientiﬁc).2.10. Measurement of intracellular reactive oxygen species (ROS)
Intracellular ROSweremeasured using oxidant-sensitiveﬂuorescent
probes. Brieﬂy, 500 000 cells were incubated without or with 200 μM
carboxy-dichlorodihydroﬂuoresceinediacetate acetyl ester (carboxy-
H2DCFDA, Molecular Probes) and 10 μM dihydroethidium (DHE) at
37 °C in 5% CO2 for 30min. Then cells were washed in phosphate buffer
saline before ﬂuorescence measurement with the LSRFortessa™ FACS
(Becton Dickinson) cytometer.2.11. Measurement of lipid peroxidation
Cell pellets (7.5 105) were suspended in 0.4% (v:v) thiobarbituric
acid, 50% acetic acid, 2 mM EDTA, and heated slightly below 100 °C for
one hour. After cooling in ice the lysate was centrifuged for 10 min at
4000 g. The ﬂuorescence of the supernatant (λex = 535 nm; λem =
595 nm) was measured with the Inﬁnite M200 plate reader (Tecan
Group Ltd, Männedorf, Switzerland).2.12. Measurements of mRNA
Total RNA was puriﬁed from KG1 and K562 cells grown in the
absence and in the presence of 200 μM deferoxamine for 24 h. Comple-
mentary DNAwas synthesized from1 μg of RNAwithmodiﬁedMoloney
Murine Leukemia virus reverse transcriptase (M-MuLV RT, Euromedex
#09-11211) and oligo(dT)12-18 primer, and diluted 30-fold. It was
ampliﬁed by real-time qPCR (C1000 Thermal Cycler CFX96, BioRad),
using validated primers and the HOT Pol Evagreen qPCR Mix Plus
(Euromedex).2.13. Statistical analysis
All quantitative variables were expressed as mean. Comparison of
data was made using the Mann–Whitney t-test. Statistical analysis
was performed using the STATVIEW® software package 5.0.
3. Results
3.1. Iron withdrawal and growth arrest
Themyeloid leukemia cell lines used in this work are fast growing in
a completemedium containingbovine serumwith endogenous Tf. K562
and KG1 cells were treated with the clinically implemented iron chela-
tor deferoxamine (DFO), with the aim of scavenging the essential metal
nutrient in a relatively short time. Preliminary experiments showed that
adding 200 μM DFO to cells growing in complete medium resulted in
growth arrest within 24 h. The number of viable cells leveled off after
treatment (Fig. 1A) with the disappearance of cells entering mitosis
(Fig. 1B,C). Additional experiments using the same DFO concentration
for a longer time, up to 72 h, indicated that cells progressively died.
When the iron chelator had been added for 24 h, the residual intracellu-
lar iron concentrationwas unable to support growth. But actively grow-
ing cells divided for at least one generationwhen the completemedium
without chelator was replaced by a minimal one devoid of iron-loaded
Tf (see Section 2.4). As expected, the above observations are not restrict-
ed to the use of DFO, since a different iron-binding chemical,
deferiprone (3-hydroxy-1,2-dimethyl-4-pyridinone, DPF), gave qualita-
tively similar results (Fig. 1).
The growth arrest induced by chelators was not paralleled by a
signiﬁcant increase of detectable oxidizing species in viable cells
(Table S1). Accordingly, lipid peroxidation was not increased, and
heme oxygenase 1 was not induced by the short term application
of the chelators (Fig. S1). Overall, these results indicate that the
iron-deprived viable cells do not experience signiﬁcant oxidative
stress.
3.2. Iron- or transferrin-triggered recovery from the iron-depleted state
Starting from the iron-depleted situation generated by the 24 h-
treatment with 200 μMDFO, iron was added back to the mediumwith-
out serum and the reversal of growth arrest was monitored by a series
of complementary experiments. As can be seen in Fig. 2, and in agree-
ment with former observations indicating that endocytosis of the
Tf–Tf receptor complex is the privileged cellular iron uptake pathway
[16], Tf was a far better mediator of iron provision to KG1 cells as com-
pared to a simple iron salt such as ferric ammonium citrate (FAC). In
these experiments, Tf is a key component of the medium since growth
did not resume in the Tf-free minimal medium (Fe = 0 in Fig. 2). At
least 10-times more iron provided by FAC was needed to increase the
cell number in similar proportions to the situation in which iron is pro-
vided by loaded Tf. Yet, in both sets of conditions, viable cells efﬁciently
recovered from the depleted situation without apparent harm and
despite the absence of serum.
In the above experimental setting, the amount of Tf and associated
iron needed to support growth can be precisely evaluated. Independent
determinations in different experiments indicated that growth of K562
cells resumed after 24 h at Tf concentrations between 10 and 20 nM
(Fig. 3A). The corresponding value for the KG1 cell line was shifted
to below 5 nM fully loaded Tf (Fig. 2B). Accordingly, monitoring
the cell cycle indicated that the proportion of G2/M cells progres-
sively increased with the Tf concentration to reach a value similar to
that displayed by actively growing cells in the presence of serum
(Fig. 3A).
Considering the very low concentrations of Tf added to resume
growth, it may be asked whether the effect is driven by added iron or
is due to the Tf protein, a strong ferric iron binder of its own. To address
Fig. 1. Comparison of growing and chelator-treated cells. Top: KG1 cells. (A) The left panel shows the increase of viable cells (%) after 24 h in the conventional (serum-containing) growth
medium (black bars) and after exposing them to either desferrioxamine (DFO, N = 6) or deferiprone (DFP) in the minimal medium devoid of serum (white bars). (B) Representative
analysis of the cell cycle before (top) and after (bottom) application of DFO. (C) Percentage of mitotic cells under normal growth conditions (−) and after the DFO-treatment (+)
(N = 4, * signiﬁcant difference p = 0.0209). Bottom: Same experiments with the K562 cell line (D–F). The difference in the fraction of mitotic cells (F) is signiﬁcant *, p = 0.0200
(N= 4).
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bound iron), was used in the replenishment experiments. Apo-Tf
concentrations as low as 15 nM were able to maintain viability of
iron-depleted K562 cells for 24 h, and to reinitiate growth as witnessed
by the re-appearance of the G2/M peak (Fig. 4). However, viability was
not maintained under these conditions, i.e. without added loaded Tf, for
more than 2 or 3 days. These experiments suggest that apo-Tf canmobilize
some non-Tf bound iron brought by the medium or trapped by cells after
treatment with the chelator. Yet, most of the non-Tf bound iron cannot
be used by cells under these conditions, since viability and growth are sup-
ported for shorter duration than in the presence of holo-Tf.
The loss of cells in G2/M was also observed by treating HeLa cells
with DFO. After iron depletion, viable cells re-entered the cell cycle
(data not shown) as a function of the amount of re-added iron-loaded
Tf at low concentrations (1–5 nM), in a range similar to that observed
with KG1 cells (Fig. 2).Thus the behavior of the cell lines upon iron recoverymay quantita-
tively vary since growth of KG1 or HeLa cells resumed at smaller Tf con-
centrations than K562 cells. But the Tf concentration range rescuing
growth arrest and death triggered by iron depletion and inducing
re-entry into the cell cycle falls within a few tens of nM of Tf, at most,
for all examined cell lines.
3.3. Molecular changes associated with iron replenishment
The iron concentration associated with cells followed the amount of
added holo-Tf (Fig. 2; Fig. 3B). Yet, a consistent shift of the Tf concentra-
tion at which iron started to accumulate was observed (Fig. 2; Fig. 3A,B)
compared to the concentrations triggering growth resumption, as
monitored by increases in cell density and the development of the
proportion of cells in the G2/M phase for instance. This indicates that
iron storage occurs only when basic cellular needs are secured,
Fig. 2. Cell growth and intracellular iron replenishment of KG1 cells according to the iron
source. Curves with black square marks represent the cell density after 24 h in minimal
medium, starting from DFO-treated cells at 105 cells/ml. Dashed lines with cross marks
represent calculated iron concentration associated with cells (see Section 2.7): the value
measured without added iron (Fe = 0) corresponds to ca. 20 pmol Fe/106 KG1 cells.
(A) Iron in the minimal growth medium provided by ferric ammonium citrate. (B) Same
experiment with iron provided by holo-Tf.
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Ferritin is the protein responsible for intracellular iron storage.
Immuno-detection of ferritin was found to follow the increase of
intra-cellular iron as expected (Fig. 3B,D). In a mirroring function, the
Tf receptor is all the more needed as iron is lacking. It thus decreased
asmore iron became available (Fig. 3C). Ferritin and Tf receptor 1 clearly
increased anddecreased, respectively, at lower Tf concentrations in KG1
cells (Fig. S2) than in K562 cells (Fig. 3).
The Iron Regulatory Proteins (IRP)were identiﬁed three decades ago
as major regulators of ferritin and Tf receptor 1 translation [17,18]. Ac-
cording to its acceptedmechanism, active IRP in iron limited conditions
are repressors of ferritin translation and enhancers of Tf receptor 1 syn-
thesis. In linewith the results of the immuno-blots for ferritin and the Tf
receptor 1, the IRP activity, but not the amount of the IRP1 protein, de-
creased as iron became available to cells via Tf (Fig. 3, Fig. S2). Changes
in the concentration of other iron regulated proteins, such as NDRG1
(Fig. S3), were also observed in these experiments, which indicates
that the implemented conditions largely dealt with iron/Tf effects rather
than with less direct mechanisms. Indeed, lipid peroxidation, inducible
hemeoxygenase (HO-1), or oxidizing species concentrations did not signif-
icantly change in anyof the samples (Table S1 andFig. S1). Thus, the behav-
ior of the studied cell lines cannot be explained by, or be associated with,
iron mobilization by increased oxidative stress and cellular damage.
Apo-Tf can maintain viable iron-depleted cells for a short time
(Fig. 4A) whereas cells without apo-Tf did not show any sign of growth
(absence of G2/M cells for instance). However, addition of apo-Tf did
not signiﬁcantly change the IRP activity (Fig. 4B), the amount of the Tf
receptor 1 (Fig. 4D), and only marginally ferritin (Fig. 4E). Also, the
iron associated with cells did not dose-dependently follow added apo-
Tf (Fig. 4C). Thus, whereas apo-Tf avoided immediate death of iron-
depleted K562 cells, it did not display the dose dependency observed
with holo-Tf (Fig. 3).3.4. Derivation of the iron concentration needed for cellular growth
The data reported in Fig. 3 and S2 call for a quantitative assess-
ment of the species under consideration. Toward this aim, it is
convenient to use a previously developed theoretical framework
[19] (and unpublished). The regulatory effect of iron on the IRP
was represented by a sigmoid of the form [Fe]n/([Fe]n + θn),
where [Fe] is the iron concentration detected by the regulatory
system, θ is a value representing the iron threshold triggering
the IRP activity (increasing below, disappearing above), and n is
a number indicating the steepness of the sigmoid. Using this
iron-dependency and assuming regulation by [Fe] has reached a
stationary state at the time of the measurement, the variations
of the IRP activity with [Fe] were adjusted according to:
IRP=IRPmax ¼ ð½Fen þ θnÞ=ððh þ 1Þ½Fen þ θnÞ ð1Þ
Derivation of this equation is presented in Appendix A. IRPmax is the
IRP activity measured without added Tf and considered to be maximal,
and h is the ratio of the kinetic constants for the disappearance of IRP
activity (the one in the presence of abundant iron divided by that in
its absence). In the case of K562 cells the best adjustment of the data
equating [Fe] in Eq. (1) to the provided Tf bound iron returned values
of θ = 61.3 (SD 15.4) nM, h = 3.95 (SD 0.7), and n ~ 2 (Fig. 5). It
means that the iron concentration modifying the IRP activity is that
afforded by ca. 30 nM of added fully loaded Tf, and that the rate of dis-
appearance of the IRP activity is 4-fold faster in the presence of iron
than in its absence. A similar treatment of the data obtained with KG1
cells returned values close to 10 nM and 4 for θ and h, respectively
(Fig. 5).
The values of h and n are similar in both cell lines (see also Table S2):
this suggests that themechanisms involved in regulating the IRP activity
are conserved in different cells. The calculated values of θ deserve
further analysis, because the correspondence between the added
Tf-bound iron and the intracellular concentration detected by IRP is
not straightforward. Fig. 3 shows that cell-associated iron started to
increase at externally added Tf values higher than those triggering the
decrease of IRP activity and the increase of the number of cells
re-engaged in the cycle. This strongly suggests that all provided iron
in the lowest Tf concentration range is readily used for biosynthetic
needs without storage. Further, for a given cell type, a single set of
parameters accounts for the sigmoidal dependence of IRP/IRPmax with
[Fe] (Fig. 5). Thus, the amount of externally provided iron and the
“IRP-detected” intracellular one are simply related and assumed to be
proportional. But, since it is difﬁcult to estimate the value of the propor-
tionality coefﬁcient from the data or from theoretical considerations, we
let intracellular [Fe] of Eq. (1) vary between 1/100 and 100-fold the ex-
ternal Tf-bound iron concentration in adjustments similar to those of
Fig. 5. Satisfactory ﬁts for the K562 data were obtained, in which h and
n did not change, and the boundaries for θ were approximated
(Table S2). If the intracellular iron concentration detected by IRP were
100-fold that provided by Tf, cells would concentrate 100-fold externally
available iron, all into the intracellular fraction detected by IRP only,
before the onset of storage. This situation seems very unlikely, as it im-
plies that ferritin is used for far higher intracellular iron concentrations
than 100-times that of externally provided Tf, i.e. in the μM range in
our experiments. It thus seems more realistic to limit this multiplicative
factor to values way lower than 100. Of note, growth resumption of
progenitors from cord blood (see below) and of both KG1 and HeLa
cells occurred at lower Tf concentrations than for K562 cells, indicating
even lower iron needs in these cases. From this analysis it may be
concluded that the concentration of intracellular, easily mobilized, and
Tf-derived iron most probably falls well below a few hundred nM to
support cellular division.
Fig. 3. Recovery of iron-depleted K562 cells after addition of holo-transferrin. (A) Re-entry in the cell cycle after 24 h of replenishment with iron-loaded Tf (Tf), as measured in different
experiments (N= 3) by integration of the G2/M peak. (B) Fold increase of the iron amount associated with the cells (N= 3). The average amount of Fe is 60 pmol/106 K562 cells in the
absence of Tf (Tf = 0). (C–E)Western blots of one representative experiment showing Tf receptor 1, ferritin, and IRP1, respectively, as a function of added Tf to iron depleted cells. S is the
sample taken at the end of iron depletion, i.e. 24 h before the other iron-rescued samples. (F) RNA electrophoretic mobility shift assay of lysates from iron replenished cells with the in-
dicated Tf concentrations in the same experiment. The positions of the shifted bands corresponding to recombinant IRP1 and IRP2 (see Fig. S2) in this assay are indicated on the right side.
Triangles are included to indicate the direction of signiﬁcant changes, but they do not imply monotonous variations.
1601E. Pourcelot et al. / Biochimica et Biophysica Acta 1853 (2015) 1596–16053.5. Transferrin dependence for ampliﬁcation of CD34+ progenitors
CD34+ progenitors were isolated from cord blood and the inﬂuence
of Tf-bound iron on growth was studied for comparison with cell lines.
The puriﬁcation procedure gave preparations with more than 80%
(mean 89.2% SD 5.3 for 13 experiments) of quiescent CD34+ cells
(Fig. 6A).
To circumvent the uncertainties in the composition of the complex
media supporting culture of CD34+ cells, a minimal medium of well-
deﬁned composition (see Section 2.5) was designed following the
pioneering work of others [20]. The puriﬁed progenitors proliferated
in the medium containing ca. 1 μM holo-Tf, with up to a 4-fold increase
of CD34+ cells after 3 days. Accordingly, the proportion of cells in the
G2/M phase meanwhile rose (Fig. 6B) from 0 after isolation to up to
8%. Ampliﬁed cells could be kept for up to 9 days in culture, even with
nM concentrations of Tf, and withmedium changes every 3 days. Omis-
sion of Tf rapidly led to cell death without ampliﬁcation or differentia-
tion. Expansion of CD34+ cells was accompanied by the increase of
the cell-associated iron concentration above 200–250 nM of added Tf,
but not below.
Treatment of ampliﬁed CD34+ cells with up to 200 μMDFO for 24 h
stopped growth (Fig. 6C), and removal of the chelator without Tf addi-
tion did not maintain viable cells (Fig. 6D). Thus, DFO-treated CD34+
cells are deﬁcient in readily available iron. But addition of holo-Tf con-
centrations as low as 5 nM maintained viable CD34+ cells and growthresumed, as shown in Fig. 6E at 15 nM. The ferritin protein also in-
creased with large iron provision, with a mirroring decay of Tf receptor
1 (Fig. 6F), as observed with cell lines (Fig. 3, Fig.S2). In experiments in
which small concentrations of either holo-Tf (e.g. Fig. 6E) or apo-Tf (e.g.
Fig. 4A) were added to the growth medium of progenitors, viability
stayed at the same level with both forms of Tf for a short time
(b2 days). Efforts to deplete serum albumin of bound cations (see
Section 2.4) left 300 nM of iron on average (SD = 75, 7 independent
measurements) in the complete minimal growth medium. Therefore,
ca. 10 timesmore iron than provided by holo-Tf is present in the growth
medium, and any form of Tf (apo- or recycling holo-) is needed tomake
a little part of non-Tf bound iron available to the cells. Yet, ampliﬁcation
of CD34+ cells increasedwith added holo-Tf, indicating that iron associ-
ated with Tf turnover was the limiting factor for progression of the cell
cycle. Congruent with the observations made with cell lines (Fig. 3;
Fig. 4; Fig. S2), it can be concluded that CD34+ progenitors enter the
cell cycle and start proliferatingwith less than 15 nM Tf, a concentration
similar to that supporting growth of KG1 and HeLa cells after DFO
chelation.
4. Discussion
The present studies provide an unprecedented opportunity to esti-
mate the amount of iron needed to support growth of hematopoietic
progenitors and of different cell lines after sufﬁcient depletion for
Fig. 4. Evolution of iron-depleted K562 cells after addition of apo-transferrin. (A) Cell cycle analysis of K562 cells, top: under standard (iron replete) conditions; middle: after iron removal
by 200 μMDFO for 24 h; bottom: after adding 15 nM apo-Tf for 24 h to DFO-treated K562 cells. (B) IRP activity as a function of added apo-Tf. The histogram of shifted IRP-Iron Responsive
Element bands is the cumulative data inwhich the intensity of these bands is related to the amount of IRP protein determined byWestern blot and set to 1 for Tf=0. The shifted bands of a
representative experiment are shown below the relevant Tf values. (C) Iron associated with iron-depleted K562 cells after adding the indicated concentrations of apo-Tf for 24 h. The av-
erage amount of Fe is 90 pmol/106 K562 cellswithout iron addition (ApoTf=0). (D) Tf receptor 1 and (E) FerritinWestern blots and cumulative amounts of the proteins relative toβ-actin
in different experiments.
Fig. 5. IronRegulatory Proteins sensitivity to iron-bound transferrin. The IRP activity at any
given concentration of added Tf was plotted relative to that without Tf, and the drawn
lines were adjusted to the experimental data with the analytical expression and the pa-
rameters reported in the text. Cumulative data from 3 different experiments for each
cell line were used for this analysis, but the points without standard deviation bars were
not present in all experiments.
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compound, such as a ﬂuorescent probe, was added to secure readouts.
Instead, a set of iron-sensitive endogenous parameters were measured
to monitor levels of functional cellular iron. Accordingly, cellular stores
were monitored by ferritin levels, and the amount of iron needed to
reinitiate growth was precisely measured by quantitatively following
the iron trafﬁcking proteins, such as Tf receptor 1, and the activity of
the cellular iron regulatory system (Iron Regulatory Proteins). The
remaining iron traces in the different conditions have been taken into
account by demonstrating the mandatory addition of iron-loaded Tf
for proportional growth, and by showing the very limited ability of
apo-Tf to mobilize residual non-Tf bound iron.4.1. Signiﬁcance of functional intra-cellular iron concentration (FIC)
The estimate of the iron amount needed to support cellular growth
(Figs. 3, 5, S2) is signiﬁcantly smaller than previous phenomenological
measurements of exchangeable iron by ﬂuorescent probes e.g. [21,22].
In a situation as complex as that afforded by cellular iron homeostasis,
it is difﬁcult to exactly knowwhich iron species are detected by ﬂuores-
cent molecules [23]. In contrast, the present experiments only monitor
endogenous systems. Hence, the two approaches certainly have their
own merits and they should be used accordingly. To acknowledge this
difference, and considering the largely accepted term of labile iron pool
(LIP) coined to the metal that can be bound by ﬂuorescent reporter-
molecules, we propose to designate by functional iron concentration
Fig. 6. Ampliﬁcation of primary CD34+ cells. Cell cycle analysis of CD34+ cells (A) after isolation, (B) after 3 days of ampliﬁcation in the complete medium, (C) as in (B) and an additional
day in the presence of 200 μM DFO, (D) as in (C) and an additional day in the complete medium without Tf, (E) as in (C) and an additional day in the complete mediumwith 15 nM Tf.
(F) Isolated CD34+ cells were ampliﬁed for 3 days, treatedwith 200 μMDFO for 24 h (S), and kept for an additional day in theminimal syntheticmedium supplementedwith 1.25 μMTf or
not (0). The indicated proteins were detected by immuno-blotting.
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mobilized for viability, and estimated here. Increases of the LIP
have often been proposed to participate to increased oxidativestress via intracellular Fenton-like chemistry, whereas the FIC
identiﬁed herein does not generate any sign of oxidative imbalance
(Table S1).
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cellular iron concentration closer to those of other essential transition
metals, including zinc which is generally found in total amounts similar
to those of iron in biological systems. Indeed, despite the relatively large
quantities of zinc present in cells (NμM), the cytosolic concentration of
the Zn2+ ions is buffered largely below nM values [24]. In the case of
iron the θ values of the FIC fall below the dissociation constants
measured for most iron-containing enzymes and proteins [25].Without
entering into a thorough discussion of this point, it is of note that the
only iron chaperones postulated in mammalian cells belong to the
poly(rC) binding proteins (PCBP) family [26]. The lowest dissociation
constant describing the binding of the ﬁrst iron atom to PCBP1 is
below 1 μM [27], and the transfer of that iron to ferritin, the ﬁrst pro-
posed substrate of iron loaded PCBP1/2, displays thermodynamic con-
stants in the 0.2–0.3 μM range. These data perfectly ﬁt in the scenario
emerging from our studies: the determined FIC is relevant under iron-
limiting conditions, before the involvement of PCBP and the need for
storage in ferritin. Thus, the idea of a FIC adds amissing link inmamma-
lian cellular iron homeostasis by depicting the available iron readily de-
livered by Tf for immediate cellular needs, i.e. below the iron
concentrations demanding storage.
4.2. Consequences for normal and pathological hematopoiesis, and other
conditions
The observations and quantitative evaluations made with the K562
and KG1 cell lines also apply to the primary cells they can be considered
to derive from. Ampliﬁcation of the CD34+ cord blood progenitors was
efﬁcient in minimal medium (Fig. 6B) with small, in the nM range, con-
centrations of Tf. The low FIC values are of relevance in pathological sit-
uations. For instance, myelodysplastic syndrome (MDS) patients often
need regular transfusions to reach a suitable circulating hemoglobin
concentration. However, this treatment is prone to induce iron overload
and a majority of these patients beneﬁt from iron chelation therapy in
terms of overall survival [28] and dependence on transfusion. Acutemy-
eloid leukemia (AML) as cause of death in non-refractory anemia with
ring sideroblasts MDS patients was annihilated by iron chelation in a
retrospective clinical analysis [29]. Hence, the AML clones likely grew
on the ample iron provision afforded by transfusions, and the continu-
ing presence of chelator counteracted this effect. Iron manipulation to
oppose growth of cancer cells should thus integrate the presently deter-
mined concentrations as target values to optimize efﬁciency while
minimizing risks. Another example is the widespread provision of
erythropoietic stimulating agents (ESA) in cancer related, radiation- or
chemotherapy-induced, anemia. Patients suffering from cancer related
anemia with low Tf saturation and medium/low ferritin may be offered
a combination of ESA and intravenous iron under various forms
(dextran, sucrose, gluconate, etc.) in a relatively short period of time
[30]. Increased hemoglobin levels and decreased needs for transfusions
are efﬁciently reached in clinical studies [30], often with increase of the
Tf saturation (and of circulating ferritin) in responding patients with
very low (b20%) values before enrollment. But the still incomplete
evaluation of intravenous iron injections, particularly in the long run,
is requested [30].
5. Conclusions
The requirement for proper iron monitoring, especially in a clinical
context, is called for by our studies, which show that even low Tf con-
centrations and small iron loads, at low nM levels, promote growth of
transformed cells. Such cells may remain after or during chemotherapy,
hence increasing the risk of relapse with sustained iron provision. Iron
chelation [31] and iron deprivation with drug delivery by targeting Tf
receptor 1 [32] afford high hopes in anti-cancer therapies. With the
presently reported information at hand, this promising ﬁeld should
focus on the differences between iron homeostasis in normal andpathological cells [33] in order to allow design of more targeted and ef-
ﬁcient treatments.
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Appendix A
The temporal evolution of active IRP has been previously described
[19] and it has the following form:
dy
dt
¼ k1− k:σ :y− k2 :y
where y is the variable representing the concentration of active IRP, k1,
k, and k2 are the kinetic constants for non-regulated production, iron-
dependent inactivation, and non-regulated degradation of IRP, respec-
tively. σ is a sigmoid function of available iron ([Fe]) and of the iron
threshold (θ) regulating the IRP activity according to:
σ ¼ Fe½ n = Fe½ n þ θn 
in which n represents the steepness of the iron regulation of IRP. Under
conditions of extreme iron shortage, as implemented after iron chela-
tion and growth arrest with onset of cell death, σ ~ 0, and, assuming
that the IRP activity has reached a stationary state (dy/dt = 0), y =
ymax = k1/k2.
After 24 h of iron replenishment, it is assumed that cells have
reached a density dependent on the externally provided iron (bound
to transferrin). This density does not increase further and it corresponds
to a steady state. This assumption appears valid for small transferrin
concentrations, since proliferation is not supported beyond this time
limit and cell death starts in the absence of further iron addition. At
higher iron concentrations it is less correct as growth continues for a
number of divisions which parallels iron provision. The steady state as-
sumption (dy/dt= 0) implies:
y
ymax
¼ k1
kσ þ k2
 k2
k1
¼ k2
kσ þ k2
¼ 1
.
kσ
k2
þ 1
 
writing h = k/k2 and developing:
y
ymax
¼ Fe½ 
n þ θn
h Fe½ n þ Fe½ n þ θn ¼
Fe½ n þ θn
hþ 1ð Þ Fe½ n þ θn
which is Eq. (1) used in Fig. 5.
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doi.org/10.1016/j.bbamcr.2015.03.009.
References
[1] N.T. Le, D.R. Richardson, The role of iron in cell cycle progression and the proliferation
of neoplastic cells, Biochim. Biophys. Acta 1603 (2002) 31–46.
[2] J.A. Cotruvo, J. Stubbe, Class I ribonucleotide reductases: metallocofactor assembly
and repair in vitro and in vivo, Annu. Rev. Biochem. 80 (2011) 733–767.
[3] A.M. Merlot, D.S. Kalinowski, D.R. Richardson, Novel chelators for cancer treatment:
where are we now? Antioxid. Redox Signal. 18 (2013) 973–1006.
[4] E. McLean, M. Cogswell, I. Egli, D. Wojdyla, B. de Benoist, Worldwide prevalence of
anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005,
Public Health Nutr. 12 (2009) 444–454.
[5] WHO, Micronutrient Deﬁciencies, 2014.
[6] L.I. Zon, Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal,
Nature 453 (2008) 306–313.
[7] Y. Ginzburg, S. Rivella, Beta-thalassemia: a model for elucidating the dynamic
regulation of ineffective erythropoiesis and iron metabolism, Blood 118 (2011)
4321–4330.
[8] N. Shenoy, N. Vallumsetla, E. Rachmilewitz, A. Verma, Y. Ginzburg, Impact of iron
overload and potential beneﬁt from iron chelation in low-risk myelodysplastic
syndrome, Blood 124 (2014) 873–881.
[9] C. Callens, S. Coulon, J. Naudin, I. Radford-Weiss, N. Boissel, E. Raffoux, P.H. Wang, S.
Agarwal, H. Tamouza, E. Paubelle, V. Asnaﬁ, J.A. Ribeil, P. Dessen, D. Canioni, O.
Chandesris, M.T. Rubio, C. Beaumont, M. Benhamou, H. Dombret, E. Macintyre, R.C.
Monteiro, I.C. Moura, O. Hermine, Targeting iron homeostasis induces cellular
differentiation and synergizes with differentiating agents in acute myeloid
leukemia, J. Exp. Med. 207 (2010) 731–750.
[10] E. Paubelle, F. Zylbersztejn, S. Alkhaeir, F. Suarez, C. Callens, M. Dussiot, F. Isnard,
M.T. Rubio, G. Damaj, N.C. Gorin, J.P. Marolleau, R.C. Monteiro, I.C. Moura, O.
Hermine, Deferasirox and vitamin d improves overall survival in elderly patients
with acute myeloid leukemia after demethylating agents failure, PLoS ONE 8
(2013) e65998.
[11] M. Roth, B. Will, G. Simkin, S. Narayanagari, L. Barreyro, B. Bartholdy, R. Tamari, C.S.
Mitsiades, A. Verma, U. Steidl, Eltrombopag inhibits the proliferation of leukemia
cells via reduction of intracellular iron and induction of differentiation, Blood 120
(2012) 386–394.
[12] X. Brazzolotto, J. Gaillard, K. Pantopoulos, M.W. Hentze, J.M. Moulis, Human
cytoplasmic aconitase (Iron regulatory protein 1) is converted into its [3Fe–4S]
form by hydrogen peroxide in vitro but is not activated for iron-responsive element
binding, J. Biol. Chem. 274 (1999) 21625–21630.
[13] C. Dycke, C. Bougault, J. Gaillard, J.P. Andrieu, K. Pantopoulos, J.M. Moulis, Human
iron regulatory protein 2 is easily cleaved in its speciﬁc domain: consequences for
the haem binding properties of the protein, Biochem. J. 408 (2007) 429–439.
[14] D.B. Lipka, M.C. Wagner, M. Dziadosz, T. Schnoder, F. Heidel, M. Schemionek, J.V.
Melo, T. Kindler, C. Muller-Tidow, S. Koschmieder, T. Fischer, Intracellular retention
of ABL kinase inhibitors determines commitment to apoptosis in CML cells, PLoS
ONE 7 (2012) e40853.[15] A. Martelli, J.M. Moulis, Zinc and cadmium speciﬁcally interfere with RNA-binding
activity of human iron regulatory protein 1, J. Inorg. Biochem. 98 (2004) 1413–1420.
[16] P. Ponka, C.N. Lok, The transferrin receptor: role in health and disease, Int. J.
Biochem. Cell Biol. 31 (1999) 1111–1137.
[17] E.A. Leibold, H.N. Munro, Cytoplasmic protein binds in vitro to a highly conserved
sequence in the 5′ untranslated region of ferritin heavy- and light-subunit
mRNAs, Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 2171–2175.
[18] T.A. Rouault, M.W. Hentze, S.W. Caughman, J.B. Harford, R.D. Klausner, Binding of a
cytosolic protein to the iron-responsive element of human ferritin messenger RNA,
Science 241 (1988) 1207–1210.
[19] N. Mobilia, A. Donzé, J.-M. Moulis, E. Fanchon, A Model of the Cellular Iron Homeo-
stasis Network Using Semi-Formal Methods for Parameter Space Exploration, EPTCS
92 (2012) 42–57.
[20] L.J. Murray, J.C. Young, L.J. Osborne, K.M. Luens, R. Scollay, B.L. Hill, Thrombopoietin,
ﬂt3, and kit ligands together suppress apoptosis of human mobilized CD34+ cells
and recruit primitive CD34+ Thy-1+ cells into rapid division, Exp. Hematol. 27
(1999) 1019–1028.
[21] O. Kakhlon, Z.I. Cabantchik, The labile iron pool: characterization, measurement, and
participation in cellular processes(1), Free Radic. Biol. Med. 33 (2002) 1037–1046.
[22] F. Petrat, H. de Groot, R. Sustmann, U. Rauen, The chelatable iron pool in living cells:
a methodically deﬁned quantity, Biol. Chem. 383 (2002) 489–502.
[23] K.P. Carter, A.M. Young, A.E. Palmer, Fluorescent sensors for measuring metal ions in
living systems, Chem. Rev. 114 (2014) 4564–4601.
[24] W.Maret, Metals on themove: zinc ions in cellular regulation and in the coordination
dynamics of zinc proteins, Biometals 24 (2011) 411–418.
[25] R.C. Hider, X. Kong, Iron speciation in the cytosol: an overview, Dalton Trans. 42
(2013) 3220–3229.
[26] S. Leidgens, K.Z. Bullough, H. Shi, F. Li, M. Shakoury-Elizeh, T. Yabe, P. Subramanian,
E. Hsu, N. Natarajan, A. Nandal, T.L. Stemmler, C.C. Philpott, Each member of the
poly-r(C)-binding protein 1 (PCBP) family exhibits iron chaperone activity toward
ferritin, J. Biol. Chem. 288 (2013) 17791–17802.
[27] H. Shi, K.Z. Bencze, T.L. Stemmler, C.C. Philpott, A cytosolic iron chaperone that
delivers iron to ferritin, Science 320 (2008) 1207–1210.
[28] R.M. Lyons, B.J. Marek, C. Paley, J. Esposito, L. Garbo, N. DiBella, G. Garcia-Manero,
Comparison of 24-month outcomes in chelated and non-chelated lower-risk
patients with myelodysplastic syndromes in a prospective registry, Leuk. Res. 38
(2014) 149–154.
[29] H.A. Leitch, C. Chan, C.S. Leger, L.M. Foltz, K.M. Ramadan, L.M. Vickars, Improved
survival with iron chelation therapy for red blood cell transfusion dependent
lower IPSS risk MDSmay bemore signiﬁcant in patients with a non-RARS diagnosis,
Leuk. Res. 36 (2012) 1380–1386.
[30] J.A. Gilreath, D.D. Stenehjem, G.M. Rodgers, Diagnosis and treatment of cancer-
related anemia, Am. J. Hematol. 89 (2014) 203–212.
[31] R.C. Hider, X. Kong, Iron: effect of overload and deﬁciency, Met. Ions Life Sci. 13
(2013) 229–294.
[32] T.R. Daniels, E. Bernabeu, J.A. Rodriguez, S. Patel, M. Kozman, D.A. Chiappetta, E.
Holler, J.Y. Ljubimova, G. Helguera, M.L. Penichet, The transferrin receptor and the
targeted delivery of therapeutic agents against cancer, Biochim. Biophys. Acta
1820 (2012) 291–317.
[33] S.V. Torti, F.M. Torti, Iron and cancer: more ore to be mined, Nat. Rev. Cancer 13
(2013) 342–355.
